Literature DB >> 8447690

Antinuclear antibodies in routine analysis: the relevance of putative clinical associations.

A J Swaak1, V Huysen, R J Smeenk.   

Abstract

Defined antinuclear antibodies (ANA), such as antibodies to Ro/SS-A, La/SS-B, Sm, and nRNP, are often present in serum samples from patients with systemic lupus erythematosus (SLE) or other connective tissue diseases (CTD). Most data on associations between the presence of these antibodies and defined disease features have been obtained with the use of predefined groups of patients. In this work the issue of disease associations was approached from a different angle: patients suspected of having CTD were selected on the presence of these ANA in their serum samples and clinical data were subsequently scored according to a defined protocol. It was then tried to relate measured ANA and clinical symptoms. No correlation was observed between the presence of antibodies to Ro/SS-A and specific clinical symptoms. The presence of antibodies to La/SS-B was associated with the diagnosis of Sjögren's syndrome combined with leukocytopenia. In patients positive for antibodies to Sm a significantly increased incidence of skin lesions, such as butterfly rashes and discoid lesions, was seen, together with signs of myocarditis. Myocarditis was also found to be associated with the presence of antibodies to nRNP. The data presented in this study show that previously reported associations of these ANA with clinical symptoms are not confirmed when unselected patients are used.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8447690      PMCID: PMC1004988          DOI: 10.1136/ard.52.2.110

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  22 in total

1.  1958 Revision of diagnostic criteria for rheumatoid arthritis.

Authors:  M W ROPES; G A BENNETT; S COBB; R JACOX; R A JESSAR
Journal:  Bull Rheum Dis       Date:  1958-12

2.  Ribonucleoprotein antibodies: frequency and clinical significance in systemic lupus erythematosus, scleroderma, and mixed connective tissue disease.

Authors:  M D Parker
Journal:  J Lab Clin Med       Date:  1973-11

3.  Reference sera for antinuclear antibodies. I. Antibodies to native DNA, Sm, nuclear RNP, and SS-B/La.

Authors:  E M Tan; M J Fritzler; J S McDougal; F C McDuffie; R M Nakamura; M Reichlin; C B Reimer; G C Sharp; P H Schur; M R Wilson; R J Winchester
Journal:  Arthritis Rheum       Date:  1982-08

4.  Patterns of clinical disease associated with antibodies to nuclear ribonucleoprotein.

Authors:  P J Maddison; H Mogavero; M Reichlin
Journal:  J Rheumatol       Date:  1978       Impact factor: 4.666

5.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee.

Authors: 
Journal:  Arthritis Rheum       Date:  1980-05

6.  The 1982 revised criteria for the classification of systemic lupus erythematosus.

Authors:  E M Tan; A S Cohen; J F Fries; A T Masi; D J McShane; N F Rothfield; J G Schaller; N Talal; R J Winchester
Journal:  Arthritis Rheum       Date:  1982-11

7.  Antibodies to Sm in patients with systemic lupus erythematosus. Correlation of Sm antibody titers with disease activity and other laboratory parameters.

Authors:  F A Barada; B S Andrews; J S Davis; R P Taylor
Journal:  Arthritis Rheum       Date:  1981-10

8.  Survivorship in systemic lupus erythematosus: effect of antibody to extractable nuclear antigen.

Authors:  M C Hochberg; C A Dorsch; E J Feinglass; M B Stevens
Journal:  Arthritis Rheum       Date:  1981-01

9.  Clinical significance of anti-Sm antibodies in systemic lupus erythematosus.

Authors:  M Beaufils; F Kouki; F Mignon; J P Camus; L Morel-Maroger; G Richet
Journal:  Am J Med       Date:  1983-02       Impact factor: 4.965

10.  Identification of a clinical subset of systemic lupus erythematosus by antibodies to the SM antigen.

Authors:  D M Winn; J F Wolfe; D A Lindberg; F H Fristoe; L Kingsland; G C Sharp
Journal:  Arthritis Rheum       Date:  1979-12
View more
  5 in total

1.  Autoantibodies in recent onset type-1 diabetic patients to a Mr 60K microsomal hepatic protein: new evidence for autoantibodies to the type-2 glucose transporter.

Authors:  M Pehuet-Figoni; F Alvarez; J F Bach; L Chatenoud
Journal:  Clin Exp Immunol       Date:  2000-11       Impact factor: 4.330

2.  Autoantibodies in black South Africans with systemic lupus erythematosus: spectrum and clinical associations.

Authors:  M Tikly; S Burgin; P Mohanlal; A Bellingan; J George
Journal:  Clin Rheumatol       Date:  1996-05       Impact factor: 2.980

3.  Autoantibodies in black South Africans with systemic lupus erythematosus: spectrum and clinical associations.

Authors:  M Tikly; S Burgin; P Mohanlal; A Bellingan; J George
Journal:  Clin Rheumatol       Date:  1996-03       Impact factor: 2.980

4.  Comparison of antinuclear antibody testing methods: immunofluorescence assay versus enzyme immunoassay.

Authors:  R A Gniewek; D P Stites; T M McHugh; J F Hilton; M Nakagawa
Journal:  Clin Diagn Lab Immunol       Date:  1997-03

5.  Comparison and variation of different methodologies for the detection of autoantibodies to nuclear antigens (ANA).

Authors:  C González; T Martin; T Arroyo; M García-Isidoro; J A Navajo; J M González-Buitrago
Journal:  J Clin Lab Anal       Date:  1997       Impact factor: 2.352

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.